We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Pulmonary Embolism Diagnosed by Improved Interpretation of Blood Tests

By LabMedica International staff writers
Posted on 10 Dec 2019
Pulmonary embolism is the sudden blockage of a major blood vessel (artery) in the lung, usually by a blood clot. More...
In most cases, the clots are small and are not deadly, but they can damage the lung and if the clot is large and stops blood flow to the lung, it can be deadly.

D-dimer is a fibrin degradation product (or FDP), a small protein fragment present in the blood after a blood clot is degraded by fibrinolysis. It is so named because it contains two D fragments of the fibrin protein joined by a cross-link. A new way to interpret blood test results in patients who are investigated for blood clots in their lungs, and this new approach applies to D-dimer blood tests, which are used by physicians to rule out the presence of a blood clot.

Scientists working with the Hamilton Health Sciences (Hamilton, ON, Canada) enrolled a total of 2,017 patients aged 18 and older who were evaluated in a study, of which 7% had pulmonary embolism on initial diagnostic testing. The average age of the patients was 52 years, and 66% were female. Of the patients in the study, 1,474 (73%) were enrolled at Hamilton Health Sciences or St. Joseph's Healthcare Hamilton. These patients, and those at other university-based clinical centers in Canada, were tested from December 2015 through May 2018 and assessed 90 days later.

The team reported that of the 1,325 patients identified by an emergency department physician as having a low (1,285 of the patients) or a moderate (40 patients) probability of having a pulmonary embolism and who had negative D-dimer results (that is, less than 1,000 or 500 ng/mL, respectively), none had venous thromboembolism during follow-up.

Clive Kearon, MB, MRCPI, FRCPC, PhD, a professor of medicine, and a senior author of the study, said, “The primary goal of diagnostic testing for pulmonary embolism is to identify which patients should be treated with anticoagulant agents and which should not. When a physician is concerned that pulmonary embolism may be present, chest imaging with CT pulmonary angiography is usually done in half of these patients. We wanted to find a way to reduce the number of CT scans that need to be done. Our analyses show that pulmonary embolism is ruled out by a D-dimer level of less than 1,000 ng/mL in patients with a low probability, and by a D-dimer level of less than 500 ng/mL in patients with a moderate probability. This way of using D-dimer testing and clinical assessment reduced the need for CT scanning by one-third.” The study was published on the November 28, 2019 in the New England Journal of Medicine.

Related Links:
Hamilton Health Sciences


Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
Steam Sterilizer
Hi Vac II Line
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The model estimated about a fivefold return in gastric cancer prevention benefits per unit invested, with cost-effectiveness maintained in higher-cost settings (Image credit: Adobe Stock)

H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention

Health systems increasingly rely on economic evidence to guide cancer prevention strategies. For gastric cancer, selecting screening approaches that can integrate with existing programs is a key policy question.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.